Cardiotoxic drugs Herceptin and doxorubicin inhibit cardiac microvascular endothelial cell barrier formation resulting in increased drug permeability
Cardiotoxicity induced by anti-cancer therapeutics is a severe, and potentially fatal, adverse reaction of the heart in response to certain drugs. Current in vitro approaches to assess cardiotoxicity have focused on analysing cardiomyocytes. More recently it has become apparent that non-cardiomyocyt...
| Published in: | Biology Open |
|---|---|
| Main Authors: | Emma L. Wilkinson, James E. Sidaway, Michael J. Cross |
| Format: | Article |
| Language: | English |
| Published: |
The Company of Biologists
2016-10-01
|
| Subjects: | |
| Online Access: | http://bio.biologists.org/content/5/10/1362 |
Similar Items
Left Ventricular Function and Echocardiographic Parameters in Patients Undergoing Chemotherapy With 5‐Fluorouracil, Anthracycline, Taxotere, and Herceptin: Prospective Cohort Study
by: Alireza Abdollahi Moghadam, et al.
Published: (2025-08-01)
by: Alireza Abdollahi Moghadam, et al.
Published: (2025-08-01)
Cardiotoxicity of doxorubicin – causes, prevention, prospects
by: Paweł Wesołowski, et al.
Published: (2022-11-01)
by: Paweł Wesołowski, et al.
Published: (2022-11-01)
Protection against Doxorubicin-Induced Cardiotoxicity by Ergothioneine
by: Irwin K. Cheah, et al.
Published: (2023-01-01)
by: Irwin K. Cheah, et al.
Published: (2023-01-01)
Doxorubicin-Induced Cardiotoxicity in Collaborative Cross (CC) Mice Recapitulates Individual Cardiotoxicity in Humans
by: Caroline J. Zeiss, et al.
Published: (2019-08-01)
by: Caroline J. Zeiss, et al.
Published: (2019-08-01)
The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients
by: M Yazici, et al.
Published: (2007-10-01)
by: M Yazici, et al.
Published: (2007-10-01)
Recent Advances in the Mechanisms of Cell Death and Dysfunction in Doxorubicin Cardiotoxicity
by: Tian-Hu Wang, et al.
Published: (2023-11-01)
by: Tian-Hu Wang, et al.
Published: (2023-11-01)
Potential Roles of Melatonin in Doxorubicin-Induced Cardiotoxicity: From Cellular Mechanisms to Clinical Application
by: Tanawat Attachaipanich, et al.
Published: (2023-02-01)
by: Tanawat Attachaipanich, et al.
Published: (2023-02-01)
The role of doxorubicin in the formation of cardiotoxicity is a consensus statement. Part II. Cardiotoxicity of doxorubicin unrelated to myocytes and cardioprotection strategy (review)
by: D. A. Andreev, et al.
Published: (2024-09-01)
by: D. A. Andreev, et al.
Published: (2024-09-01)
Therapeutic Potential of Ginsenosides in Anthracycline-Induced Cardiotoxicity
by: Rongrong Bai, et al.
Published: (2025-06-01)
by: Rongrong Bai, et al.
Published: (2025-06-01)
Macrotroponin interference and association with cardiotoxicity in patients receiving cardiotoxic breast cancer therapy: a pilot study
by: Andrea Soosaipillai, et al.
Published: (2025-02-01)
by: Andrea Soosaipillai, et al.
Published: (2025-02-01)
Anthracycline-induced cardiotoxicity – primary preventive options. An overview
by: S. Slavcheva
Published: (2024-05-01)
by: S. Slavcheva
Published: (2024-05-01)
Cardiotoxicity: Importance of biomarkers
by: Kostadinović Jelena, et al.
Published: (2023-01-01)
by: Kostadinović Jelena, et al.
Published: (2023-01-01)
Pyridoxamine Limits Cardiac Dysfunction in a Rat Model of Doxorubicin-Induced Cardiotoxicity
by: Sibren Haesen, et al.
Published: (2024-01-01)
by: Sibren Haesen, et al.
Published: (2024-01-01)
Echocardiographic strategy for early detection of cardiotoxicity of doxorubicin: a prospective observational study
by: Diogo Pereira Santos Sampaio, et al.
Published: (2022-10-01)
by: Diogo Pereira Santos Sampaio, et al.
Published: (2022-10-01)
Beneficial Effects of Oral Carbon Monoxide on Doxorubicin‐Induced Cardiotoxicity
by: Rodrigo W. Alves de Souza, et al.
Published: (2024-05-01)
by: Rodrigo W. Alves de Souza, et al.
Published: (2024-05-01)
Mild hyperthermia influence on Herceptin® properties
by: Escoffre Jean-Michel, et al.
Published: (2015-03-01)
by: Escoffre Jean-Michel, et al.
Published: (2015-03-01)
The beneficial role of exercise in preventing doxorubicin-induced cardiotoxicity
by: Samantha L. Gaytan, et al.
Published: (2023-03-01)
by: Samantha L. Gaytan, et al.
Published: (2023-03-01)
The Role of Doxorubicin in the Formation of Cardiotoxicity – Generally Accepted Statement. Part I. Prevalence and Mechanisms of Formation (Review)
by: D. A. Andreev, et al.
Published: (2024-03-01)
by: D. A. Andreev, et al.
Published: (2024-03-01)
Trastuzumab and ECG Changes Dilemma
by: Azin Alizadehasl, et al.
Published: (2023-04-01)
by: Azin Alizadehasl, et al.
Published: (2023-04-01)
Assessment of anthracycline-induced long-term cardiotoxicity in patients with hematological malignancies
by: Aws Sabah Al-Rubaye, et al.
Published: (2019-01-01)
by: Aws Sabah Al-Rubaye, et al.
Published: (2019-01-01)
POSSIBILITY OF DRUG PREVENTION ANTHRACYCLINE-INDUCED CARDIOTOXICITY
by: V. I. Chernov, et al.
Published: (2016-02-01)
by: V. I. Chernov, et al.
Published: (2016-02-01)
Cardiotoxicity of anticancer drugs and radiotherapy in patients with hematologic malignancies and solid tumors
by: L. M. Kogoniya, et al.
Published: (2022-07-01)
by: L. M. Kogoniya, et al.
Published: (2022-07-01)
Anthracycline-induced cardiotoxicity: mechanisms, monitoring, and prevention
by: Yun Qiu, et al.
Published: (2023-12-01)
by: Yun Qiu, et al.
Published: (2023-12-01)
microRNA-377 Signaling Modulates Anticancer Drug-Induced Cardiotoxicity in Mice
by: John Henderson, et al.
Published: (2021-08-01)
by: John Henderson, et al.
Published: (2021-08-01)
Anthracycline-Induced Cardiotoxicity
by: Radomír Hrdina, et al.
Published: (2000-01-01)
by: Radomír Hrdina, et al.
Published: (2000-01-01)
Hypofunction of macrophage chemotaxis contributes to defective efficacy of herceptin in HER2-positive breast cancer patients
by: Yu Song, et al.
Published: (2024-12-01)
by: Yu Song, et al.
Published: (2024-12-01)
Challenges in the implementation of cardio-oncology trials: lessons learnt from investigating statins in the prevention of anthracycline cardiotoxicity
by: John Lee, et al.
Published: (2024-12-01)
by: John Lee, et al.
Published: (2024-12-01)
Cardiotoxicity in patients with early breast cancer treated with adjuvant trastuzumab
by: Joanna Kufel-Grabowska, et al.
Published: (2022-10-01)
by: Joanna Kufel-Grabowska, et al.
Published: (2022-10-01)
Racial and Ethnic Disparities in Cardiotoxicity in Patients With Cancer Treated With Anthracyclines
by: Lili Zhang, et al.
Published: (2025-04-01)
by: Lili Zhang, et al.
Published: (2025-04-01)
Incidence and risk factors of anthracycline-induced cardiotoxicity in long-term survivors of pediatric cancer: A population based cohort study
by: Prathana Nathan, et al.
Published: (2022-12-01)
by: Prathana Nathan, et al.
Published: (2022-12-01)
Genetic basis of anthracyclines cardiotoxicity: Literature review
by: M. Yu. Sinitsky, et al.
Published: (2021-10-01)
by: M. Yu. Sinitsky, et al.
Published: (2021-10-01)
Anticancer drugs and cardiotoxicity: the role of cardiomyocyte and non-cardiomyocyte cells
by: Chrysa Koukorava, et al.
Published: (2024-07-01)
by: Chrysa Koukorava, et al.
Published: (2024-07-01)
An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity
by: Sicong Xie, et al.
Published: (2024-06-01)
by: Sicong Xie, et al.
Published: (2024-06-01)
Durable and Complete Response to Herceptin Monotherapy in Patients with Metastatic Gastroesophageal Cancer
by: Brenen P. Swofford, et al.
Published: (2017-12-01)
by: Brenen P. Swofford, et al.
Published: (2017-12-01)
Lifestyle and Pharmacological Interventions to Prevent Anthracycline-Related Cardiotoxicity in Cancer Patients
by: Luigi Spadafora, et al.
Published: (2025-06-01)
by: Luigi Spadafora, et al.
Published: (2025-06-01)
MicroRNAs in anthracycline cardiotoxicity: biomarkers, mechanisms, and therapeutic advances
by: Hongyun Mao, et al.
Published: (2025-08-01)
by: Hongyun Mao, et al.
Published: (2025-08-01)
Correction: An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity
by: Sicong Xie, et al.
Published: (2025-09-01)
by: Sicong Xie, et al.
Published: (2025-09-01)
Temporal Dynamics of Extracellular Matrix Remodeling in Anthracycline-Induced Cardiotoxicity
by: Fibi Meshrkey, et al.
Published: (2025-09-01)
by: Fibi Meshrkey, et al.
Published: (2025-09-01)
Cardiotoxicity in Breast Cancer Therapy: Risks, Mechanisms, and Prevention Strategies
by: Annisa Eka Fitrianti, et al.
Published: (2025-08-01)
by: Annisa Eka Fitrianti, et al.
Published: (2025-08-01)
Cardioprotective potential of botanical agents against anthracycline-induced cardiotoxicity
by: Parisa Firoozbakhsh, et al.
Published: (2024-05-01)
by: Parisa Firoozbakhsh, et al.
Published: (2024-05-01)
Similar Items
-
Left Ventricular Function and Echocardiographic Parameters in Patients Undergoing Chemotherapy With 5‐Fluorouracil, Anthracycline, Taxotere, and Herceptin: Prospective Cohort Study
by: Alireza Abdollahi Moghadam, et al.
Published: (2025-08-01) -
Cardiotoxicity of doxorubicin – causes, prevention, prospects
by: Paweł Wesołowski, et al.
Published: (2022-11-01) -
Protection against Doxorubicin-Induced Cardiotoxicity by Ergothioneine
by: Irwin K. Cheah, et al.
Published: (2023-01-01) -
Doxorubicin-Induced Cardiotoxicity in Collaborative Cross (CC) Mice Recapitulates Individual Cardiotoxicity in Humans
by: Caroline J. Zeiss, et al.
Published: (2019-08-01) -
The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients
by: M Yazici, et al.
Published: (2007-10-01)
